Latest news
Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas
Debiopharm and EPFL honour Dr Eduard Batlle with the “Debiopharm Life Sciences Award”
The Japanese Cancer Association (JCA) and Debiopharm honour Professors Masanori Hatakeyama and Johji Inazawa with the 2006 JCA-Mauvernay Award
Debiopharm granted European Orphan Drugs Status for Debio-0513 (PTR-262) for Myasthenia Gravis
Debiopharm applies for first europe marketing authorisation for Sanvar® in France
Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets
Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men
The Debiopharm Group and Sigma-Tau sign R&D and commercial agreement for Istaroxime in acute heart failure syndromes